Immutep Ltd., a late-stage immunotherapy company, has announced the successful attainment of a grant from the Polish government for its EFTISARC-NEO Phase II trial. This trial evaluates the combination of eftilagimod alfa (efti) with radiotherapy and KEYTRUDA® (pembrolizumab) in the treatment of resectable soft tissue sarcoma $(STS.UK)$. The funding, awarded by the Polish Medical Research Agency program, supports this innovative study, which has shown promising results by exceeding its primary endpoint of tumour hyalinization/fibrosis. This development highlights the potential of the novel combination therapy in addressing the high unmet medical need in STS, an aggressive orphan cancer.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。